GENESIS Pharma erweitert strategische Vertriebspartnerschaft mit Alnylam Pharmaceuticals bei RNAi-Therapeutika auf skandinavische Länder

Key Takeaway: GENESIS Pharma has expanded its strategic distribution partnership with Alnylam Pharmaceuticals to include Scandinavian countries for RNAi therapeutics. This partnership aims to enhance the availability of innovative treatments in the region. The collaboration reflects a commitment to advancing RNAi technology in new markets.